Sensorineural hearing loss in patients with cystic fibrosis

被引:36
作者
Cheng, Alan G. [1 ,4 ]
Johnston, Patrick R. [2 ]
Luz, Jennifer [1 ]
Uluer, Ahmet [3 ]
Fligor, Brian [1 ]
Licameli, Greg R. [1 ,4 ]
Kenna, Margaret A. [1 ,4 ]
Jones, Dwight T. [1 ,4 ]
机构
[1] Childrens Hosp, Dept Otolaryngol & Commun Enhancement, Boston, MA 02115 USA
[2] Childrens Hosp, Clin Res Program, Boston, MA 02115 USA
[3] Childrens Hosp, Dept Pulm Med, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA
关键词
AMINOGLYCOSIDE-INDUCED OTOTOXICITY; OTOACOUSTIC EMISSIONS; THERAPY; AZITHROMYCIN;
D O I
10.1016/j.otohns.2009.03.020
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
OBJECTIVE: To determine the prevalence of sensorineural hearing loss (SNHL) in cystic fibrosis (CF) patients and its relationship to antibiotic use. STUDY DESIGN: Case series with chart review. SETTING: Tertiary care pediatric hospital. SUBJECTS AND METHODS: We reviewed the medical records of CF patients seen in our children's hospital between March 1994 and December 2007. Data collected included patient demographics, audiograms, tympanograms, genotype, and use of potentially ototoxic antibiotics. RESULTS: Seven of 50 (14%) patients had SNHL. Three percent of patients who received <= 10 courses of intravenous aminoglycosides had SNHL versus 43 percent of those who received >10 courses (P < 0.01). No patients who received five or fewer courses of nasal irrigation with aminoglycosides had SNHL versus 23 percent of those who received more than five courses (P < 0.05). Nine percent of patients who received five or fewer courses of macrolides had SNHL versus 60 percent of those who received more than five courses (P = 0.079). CONCLUSION: CF patients receiving aminoglycosides are at high risk for developing SNHL. (C) 2009 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved.
引用
收藏
页码:86 / 90
页数:5
相关论文
共 20 条
  • [1] DRUG-INDUCED OTOTOXICITY
    BRUMMETT, RE
    [J]. DRUGS, 1980, 19 (06) : 412 - 428
  • [2] Inhaled tobramycin (TOBI®) -: A review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis
    Cheer, SM
    Waugh, J
    Noble, S
    [J]. DRUGS, 2003, 63 (22) : 2501 - 2520
  • [3] Cheng Alan G, 2005, Curr Opin Otolaryngol Head Neck Surg, V13, P343, DOI 10.1097/01.moo.0000186799.45377.63
  • [4] CONTOPOULOSIOAN.DG, 2004, PEDIATRICS, V114
  • [5] OTOTOXICITY OF AMINOGLUCOSIDE ANTIBIOTICS IN LONG-TERM TREATMENT FOR CYSTIC-FIBROSIS
    CRIFO, S
    ANTONELLI, M
    GAGLIARDI, M
    LUCARELLI, N
    MARCOLINI, P
    [J]. INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 1980, 2 (03) : 251 - 253
  • [6] FORMANFRANCO B, 1979, ARCH OTOLARYNGOL, V105, P338
  • [7] The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro
    Ichimiya, T
    Takeoka, K
    Hiramatsu, K
    Hirai, K
    Yamasaki, T
    Nasu, M
    [J]. CHEMOTHERAPY, 1996, 42 (03) : 186 - 191
  • [8] Effects of chronic tobramycin treatment on distortion product otoacoustic emissions
    Katbamna, B
    Homnick, DN
    Marks, JH
    [J]. EAR AND HEARING, 1999, 20 (05) : 393 - 402
  • [9] Macrolides as immunomodulatory medications for the therapy of chronic lung diseases
    Lopez-Boado, Yolanda S.
    Rubin, Bruce K.
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2008, 8 (03) : 286 - 291
  • [10] Untitled
    Mamikoglu, B
    Mamikoglu, O
    [J]. ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2001, 110 (01) : 102 - 102